ArticleChina CDC weekly2025
Evaluations of Community-based Healthcare Management for Patients with Chronic Viral Hepatitis - Shanghai Municipality, China, 2012-2023.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Current strategies for chronic viral hepatitis prevention and control include immunization, prevention of mother-to-child transmission, expanded testing, antiviral therapy, and national drug price negotiations. To advance high-quality, integrated prevention and treatment services, a decentralized service delivery approach may be beneficial. What is added by this report?: The chronic viral hepatitis community-based healthcare management program in Shanghai delivered comprehensive service packages across 4 categories encompassing 10 distinct interventions, including epidemiological investigation, health education, free testing, community dispensing services, and immunization to family caregivers. The enrolled patients increased substantially from baseline, and antiviral treatment utilization rates reached 64.5% and 58.2% in 2019 and 2023 from 24.5% in 2012. Concurrently, abnormality rates for hepatitis B virus deoxyribonucleic acid (HBV DNA), alanine aminotransferase (ALT), total bilirubin (TBIL), and hepatic fibrosis indices decreased significantly. The 2023 aMAP score demonstrated a significant reduction in hepatocellular carcinoma risk among patients under management. Additionally, community dispensing services were accessed by 14.1% (2019) and 18.2% (2023) of enrolled patients. What are the implications for public health practice?: The community-based healthcare management program could effectively decentralize hepatitis-related testing and treatment services, and create a favorable environment for the viral hepatitis elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.